Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: marimastat, cts-1027, rebimastat | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 35 Parkinson's papers of 28,617 | 0.53 |
| pathways Reactome | 8 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 6736
Sealed predictions
- MMP2 in dopamine neurons, braak+0.12 (p 0.750) → -0.18 (p 0.638)receipt 6744
Swarm cases
receipt 6744: MMP2 in dopamine neurons, braak
- power
- full sample -0.06 (p 0.800, n 18), 95% CI -0.52 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.767, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.23 (p 0.360, n 18). could be the mix.
- skeptic
- leave-one-out range -0.19 to +0.06, sign flips 4; without severely affected donors -0.06 (p 0.800, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MMP2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts